Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Ramelteon is a melatonin receptor agonist used to treat insomnia. Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).
- Mechanism
- Curator reviewed
Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors, and lower selectivity for the MT3 receptor. Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT1 receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT2 receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT1 and MT2 receptors are associated with the sleep-wake cycle, MT3 has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.
- Primary indication
- For the treatment of insomnia characterized by difficulty with sleep onset.Curator reviewed · 1 structured indication
- Formula / weight
- C16H21NO2 · 259.3434 g/mol (avg)
- First approval
- United States, 2005
- Code names
- TAK-375
- Brand names
- Rozerem
Resolves to
YLXDSYKOBKBWJQ-LBPRGKRZSA-NSMILESCCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Ramelteon, and which of those have an active Phase 3 trial?